← Back to Clinical Trials
Recruiting Phase 3 NCT06358313

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke

Trial Parameters

Condition Ischemic Stroke
Sponsor Kafrelsheikh University
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 600
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2024-04-10
Completion 2025-12-10
Interventions
Atorvastatin 40mgRosuvastatin 20mg

Brief Summary

Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever moderate and moderate to severe stroke patients treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse effects.

Eligibility Criteria

Inclusion Criteria: * males and females aged 18-75 * first-ever moderate and Moderate-to-severe Ischemic Stroke * Patients are not eligible for rt-PA treatment Exclusion Criteria: * The investigators excluded patients who had rapidly resolving symptoms before imaging results, and patients with a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit). * the investigators excluded patients who had clinical seizures at the onset of their stroke, as well as those who had symptoms of any major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks, and those who were on warfarin, regular ticagrelor during the week before admission, or chemotherapy within the previous year. * The investigators excluded patients with active peptic ulcers, GIT surgery, bleeding history within the last year, and those with a history of major surgery within th

Related Trials